Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.55 |
| ▸ | HTR1B | P28222 | 5/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 2/20 | 0.50 |
| ▸ | OGG1 | O15527 | 1/20 | 0.50 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
| ▸ | BCL2 | P10415 | 2/20 | 0.49 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.49 |
| ▸ | BAD | Q92934 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600098 | 1.00 | KDM4E (0.59) | KDM4EALDH1A1HPGDTDP1MRGPRX4 | |
| SCHEMBL29865765 | 0.85 | KDM4E (0.70) | KDM4EALDH1A1HPGDTDP1MRGPRX4 | |
| SCHEMBL2925236 | 0.85 | KDM4E (0.70) | KDM4EALDH1A1HPGDTDP1MRGPRX4 | |
| SCHEMBL6224144 | 0.84 | ALDH1A1 (0.73) | KDM4EALDH1A1HPGDTDP1MRGPRX4 | |
| SCHEMBL4902115 | 0.82 | KDM4E (0.60) | KDM4EALDH1A1HPGDTDP1KCNA3 | |
| SCHEMBL2925774 | 0.81 | HTR1B (0.62) | KDM4EALDH1A1HPGDTDP1KCNA3 | |
| SCHEMBL29865493 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1HPGDTDP1KCNA3 | |
| SCHEMBL5488944 | 0.81 | KDM4E (0.68) | KDM4EALDH1A1HPGDTDP1KCNA3 | |
| SCHEMBL6331711 | 0.81 | KDM4E (0.58) | KDM4EALDH1A1HPGDTDP1KCNA3 | |
| SCHEMBL7278832 | 0.81 | KDM4E (0.66) | KDM4EALDH1A1HPGDTDP1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117451880-A | Method for measuring dapoxetine hydrochloride impurity by using supercritical fluid chromatography | 海南卓力制药有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-116715593-A | Optimized preparation method of dapoxetine hydrochloride and intermediate thereof | 北京悦康科创医药科技股份有限公司 | 2023-09-08 | — | — | CN | claimed |
| CN-117705964-A | Dapoxetine hydrochloride and analysis method of preparation thereof | 武汉九珑人福药业有限责任公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117451880-A | Method for measuring dapoxetine hydrochloride impurity by using supercritical fluid chromatography | 海南卓力制药有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230295673-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-09-21 | — | — | US | disclosed |
| US-20230295673-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-09-21 | — | — | US | disclosed |
| CN-116715593-A | Optimized preparation method of dapoxetine hydrochloride and intermediate thereof | 北京悦康科创医药科技股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| US-20220315961-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2022-10-06 | — | — | US | disclosed |
| US-11377673-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2015073555-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS, INC. (US) | 2015-05-21 | — | — | WO | disclosed |
| US-20150132807-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-05-14 | — | — | US | disclosed |
| US-20150132807-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2015-05-14 | — | — | US | disclosed |
| US-20130302859-A1 | Engineered imine reductases and methods for the reductive animation of ketone and amine compounds. | CODEXIS,INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302859-A1 | Engineered imine reductases and methods for the reductive animation of ketone and amine compounds. | CODEXIS,INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-6806378-B2 | CATALYST SYSTEM AND A PROCESS FOR THE PREPARATION OF A NONRACEMIC CHIRAL ALCOHOL BY HYDROGENATION OF A KETONE USING THE CATALYST SYSTEM, WHEREIN THE CATALYST SYSTEM COMPRISES RUTHENIUM, A NONRACEMIC CHIRAL DIPHOSPHINE LIGAND, AN | DSM N.V. (NL) | 2004-10-19 | — | — | US | disclosed |
| EP-1465726-A1 | PROCESS FOR PREPARING NONRACEMIC CHIRAL ALCOHOLS | DSM IP Assets B.V. (NL) | 2004-10-13 | — | — | EP | disclosed |
| US-20030171213-A1 | Process for preparing nonracemic chiral alcohols | DSM N.V. (NL) | 2003-09-11 | — | — | US | disclosed |
| WO-2003061824-A1 | PROCESS FOR PREPARING NONRACEMIC CHIRAL ALCOHOLS | DSM IP ASSETS B.V. (NL) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802274-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | AKR1C4, AKR7A2, AKR1C2 | KDM4E 1354/4885ALDH1A1 162/4885HPGD 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.